智通财经APP讯，泰达生物(08189)发布公告，截至2026年6月30日止6个月集团预期取得：收入约人民币2.9亿元至人民币3亿元，较截至2025年6月30日止6个月(去年同期)的收入约人民币2.26亿元，增加约28%至33%;及公司拥有人应占净利润约人民币700万元至人民币1000万元，较去年同期公司拥有人应占亏损约人民币600万元，增加约209%至256%, 实现扭亏为盈。
报告期内收入及公司拥有人应占净利润增长主要来自于AI生命健康业务的快速扩展。报告期内AI生命健康业务取得收入约人民币1亿元至人民币1.1亿元，公司拥有人应占净利润约人民币1000万元到1200万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.